NCT06735118 Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver
| NCT ID | NCT06735118 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yunnan Cancer Hospital |
| Condition | Non-Alcoholic Fatty Liver Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2023-12-25 |
| Primary Completion | 2024-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2023-12-25 with a primary completion date of 2024-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment. The main questions it aims to answer are:How does the liver fat fraction change before and after chemotherapy? In this study, patients undergoing mDixon Quant scanning are subjected to fully automated segmentation and measurement of liver fat content using artificial intelligence.
Eligibility Criteria
Inclusion Criteria: 1. CT/B ultrasound showed no fatty liver 2. No MRI contraindications, including pacemaker, stent, metal implant, or claustrophobia 3. Received neoadjuvant/adjuvant chemotherapy Exclusion Criteria: 1. Missing follow-up information 2. Liver lesions (metastases, hemangioma, etc.) 3. Poor image quality
Contact & Investigator
Lianhua Ye
STUDY DIRECTOR
Ethics Committee of Yunnan Provincial Cancer Hospital
Frequently Asked Questions
Who can join the NCT06735118 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Non-Alcoholic Fatty Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06735118 currently recruiting?
Yes, NCT06735118 is actively recruiting participants. Contact the research team at liulizhu2022@163.com for enrollment information.
Where is the NCT06735118 trial being conducted?
This trial is being conducted at Kunming, China.
Who is sponsoring the NCT06735118 clinical trial?
NCT06735118 is sponsored by Yunnan Cancer Hospital. The principal investigator is Lianhua Ye at Ethics Committee of Yunnan Provincial Cancer Hospital. The trial plans to enroll 120 participants.